Marker Therapeutics (MRKR) Liabilities from Discontinued Operations (2022 - 2023)
Marker Therapeutics (MRKR) posted quarterly Liabilities from Discontinued Operations of 260280.0 for Q2 2023, down 96.3% quarter-over-quarter from 7039338.0 in Q4 2022.
Marker Therapeutics (MRKR) Liabilities from Discontinued Operations (2022 - 2023) Analysis & Trends
Marker Therapeutics (MRKR) has reported Liabilities from Discontinued Operations for 2 consecutive years, with 260280.0 the latest figure, recorded in Q2 2023.
- In Q2 2023, Liabilities from Discontinued Operations changed N/A year-over-year to 260280.0; the TTM figure through Jun 2023 stood at 260280.0 (changed N/A YoY), while the FY2022 annual figure was 7039338.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations fell to 260280.0 in Q2 2023 per MRKR's latest filing, from 7039338.0 in the prior quarter.
- Across five years, Liabilities from Discontinued Operations topped out at 7039338.0 in Q4 2022 and bottomed at 260280.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Marker Therapeutics | 27.04 Mn | 15.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 260,280.00 |
| Jun 30, 2023 | 260,280.00 |
| Dec 31, 2022 | 7.04 Mn |
| Dec 31, 2022 | 7.04 Mn |